Celldex Therapeutics (CLDX) Long-Term Debt Repayments (2011)

Celldex Therapeutics' (CLDX) quarterly Long-Term Debt Repayments came in at $12.5 million in Q1 2011.

Celldex Therapeutics (CLDX) Long-Term Debt Repayments (2011) Analysis & Trends

Celldex Therapeutics' Long-Term Debt Repayments history runs 1 years deep, the most recent figure standing at $12.5 million for Q1 2011.

On a quarterly basis, Long-Term Debt Repayments changed N/A year-over-year to $12.5 million in Q1 2011; TTM through Dec 2011 was $12.5 million, a N/A change from a year earlier, with the FY2011 full-year figure at $12.5 million, changed N/A from the prior year.
Long-Term Debt Repayments steadied at $12.5 million in Q1 2011 per CLDX's latest filing.
Across five years, Long-Term Debt Repayments topped out at $12.5 million in Q1 2011 and bottomed at $12.5 million in Q1 2011.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	7.64 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Celldex Therapeutics	1.72 Mn	1.72 Mn	-1.44 Mn	-

Download Data

Date	Value
Mar 31, 2011	12.50 Mn
Mar 31, 2011	12.50 Mn